Australian Clinical Labs Limited (ACL.AX)
AUD 3.06
(7.37%)
AUD 3.06
(7.37%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 | 0.12 AUD | -33.33% |
| 2023 | 0.18 AUD | -79.78% |
| 2022 | 0.89 AUD | 122.5% |
| 2021 | 0.40 AUD | 100.0% |
| 2020 | 0.20 AUD | 484.62% |
| 2019 | -0.05 AUD | -16.85% |
| 2018 | -0.04 AUD | 62.61% |
| 2017 | -0.12 AUD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 0.02 AUD | 100.81% |
| 2024 FY | - AUD | -33.33% |
| 2024 Q3 | 0.05 AUD | 94.33% |
| 2024 Q1 | 0.01 AUD | -76.48% |
| 2024 Q4 | 0.05 AUD | -0.42% |
| 2023 Q4 | 0.05 AUD | 101.15% |
| 2023 FY | - AUD | -79.78% |
| 2023 Q3 | 0.03 AUD | -80.0% |
| 2023 Q1 | 0.06 AUD | -73.63% |
| 2023 Q2 | 0.13 AUD | 105.37% |
| 2022 Q2 | 0.65 AUD | 103.13% |
| 2022 Q1 | 0.32 AUD | 1851.22% |
| 2022 FY | - AUD | 122.5% |
| 2022 Q4 | 0.24 AUD | 100.0% |
| 2022 Q3 | 0.12 AUD | -81.54% |
| 2021 FY | - AUD | 100.0% |
| 2021 Q3 | 0.01 AUD | -96.29% |
| 2021 Q2 | 0.28 AUD | 40.0% |
| 2021 Q4 | 0.02 AUD | 57.69% |
| 2021 Q1 | 0.20 AUD | -9.09% |
| 2020 Q2 | -0.02 AUD | 0.0% |
| 2020 FY | - AUD | 484.62% |
| 2020 Q4 | 0.22 AUD | 115.69% |
| 2020 Q3 | 0.10 AUD | 745.57% |
| 2020 Q1 | - AUD | 0.0% |
| 2019 FY | - AUD | -16.85% |
| 2018 FY | - AUD | 62.61% |
| 2017 FY | - AUD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| BCAL Diagnostics Limited | -0.03 AUD | 561.538% |
| Genetic Signatures Limited | -0.11 AUD | 209.091% |
| Genetic Technologies Limited | -0.09 AUD | 232.013% |
| Healius Limited | -0.98 AUD | 112.245% |
| Imagion Biosystems Limited | -0.41 AUD | 129.268% |
| Integral Diagnostics Limited | -0.26 AUD | 146.154% |
| INOVIQ Ltd | -0.07 AUD | 269.252% |
| Microba Life Sciences Limited | -0.05 AUD | 346.914% |
| Monash IVF Group Limited | -0.02 AUD | 814.286% |
| Rhythm Biosciences Limited | -0.03 AUD | 500.0% |
| Sonic Healthcare Limited | 1.07 AUD | 88.785% |